$GMED
GLOBUS MEDICAL INC

2024 Q3 Form 10-Q Financial Statement

#000156276224000199 Filed on August 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $625.7M $629.7M
YoY Change 63.1% 115.93%
Cost Of Revenue $270.5M $260.0M
YoY Change 99.8% 240.04%
Gross Profit $355.2M $369.7M
YoY Change 43.08% 71.82%
Gross Profit Margin 56.77% 58.7%
Selling, General & Admin $240.7M $238.1M
YoY Change 54.12% 98.32%
% of Gross Profit 67.78% 64.42%
Research & Development $35.38M $37.70M
YoY Change 20.63% 76.6%
% of Gross Profit 9.96% 10.2%
Depreciation & Amortization $36.87M $33.88M
YoY Change 56.06% 87.44%
% of Gross Profit 10.38% 9.17%
Operating Expenses $276.1M $320.0M
YoY Change 11.41% 1399.18%
Operating Profit $48.10M $49.62M
YoY Change 11805.45% -74.39%
Interest Expense $9.504M -$3.038M
YoY Change 265.54% -139.22%
% of Operating Profit 19.76% -6.12%
Other Income/Expense, Net $8.934M -$2.041M
YoY Change 319.24% -385.06%
Pretax Income $57.03M $47.58M
YoY Change 2149.78% -36.28%
Income Tax $5.196M $15.82M
% Of Pretax Income 9.11% 33.25%
Net Earnings $51.84M $31.76M
YoY Change 5093.99% -44.97%
Net Earnings / Revenue 8.28% 5.04%
Basic Earnings Per Share $0.38 $0.23
Diluted Earnings Per Share $0.38 $0.23
COMMON SHARES
Basic Shares Outstanding 135.4M 135.1M
Diluted Shares Outstanding 138.1M 137.0M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $694.7M $492.9M
YoY Change 48.15% -19.56%
Cash & Equivalents $622.8M $410.4M
Short-Term Investments $71.94M $82.51M
Other Short-Term Assets $50.92M $46.21M
YoY Change 6.98% 134.77%
Inventory $717.7M $770.5M
Prepaid Expenses
Receivables $588.0M $611.8M
Other Receivables $5.149M $2.498M
Total Short-Term Assets $2.057B $1.924B
YoY Change 7.26% 59.0%
LONG-TERM ASSETS
Property, Plant & Equipment $567.8M $571.8M
YoY Change -6.44% 130.51%
Goodwill $1.432B $1.454B
YoY Change 27.55% 630.96%
Intangibles $842.8M $866.6M
YoY Change -33.2% 1478.41%
Long-Term Investments $12.30M $27.80M
YoY Change -95.54% -92.9%
Other Assets $76.64M $77.57M
YoY Change 10.31% 64.29%
Total Long-Term Assets $3.030B $3.070B
YoY Change -11.9% 206.24%
TOTAL ASSETS
Total Short-Term Assets $2.057B $1.924B
Total Long-Term Assets $3.030B $3.070B
Total Assets $5.086B $4.994B
YoY Change -5.04% 125.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $57.54M $67.16M
YoY Change -33.82% 98.64%
Accrued Expenses $255.3M $215.9M
YoY Change 15.15% 140.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $438.2M $431.5M
YoY Change 72929.5%
Total Short-Term Liabilities $818.1M $794.1M
YoY Change 90.81% 411.63%
LONG-TERM LIABILITIES
Long-Term Debt $709.0K $684.0K
YoY Change -99.83%
Other Long-Term Liabilities $22.98M $25.21M
YoY Change 2.6% 74.72%
Total Long-Term Liabilities $22.98M $25.21M
YoY Change 2.6% 74.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $818.1M $794.1M
Total Long-Term Liabilities $22.98M $25.21M
Total Liabilities $1.017B $1.017B
YoY Change -13.0% 347.42%
SHAREHOLDERS EQUITY
Retained Earnings $1.126B $1.074B
YoY Change -16.43% -20.22%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.069B $3.976B
YoY Change
Total Liabilities & Shareholders Equity $5.086B $4.994B
YoY Change -5.04% 125.71%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $51.84M $31.76M
YoY Change 5093.99% -44.97%
Depreciation, Depletion And Amortization $36.87M $33.88M
YoY Change 56.06% 87.44%
Cash From Operating Activities $203.7M $54.26M
YoY Change 303.28% 54.9%
INVESTING ACTIVITIES
Capital Expenditures $41.95M $27.80M
YoY Change 95.13% 55.57%
Acquisitions
YoY Change
Other Investing Activities $26.99M $17.42M
YoY Change -145.43% -75.15%
Cash From Investing Activities -$14.97M -$10.38M
YoY Change -81.48% -119.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.58M 8.709M
YoY Change 1298.79% 703.41%
NET CHANGE
Cash From Operating Activities 203.7M 54.26M
Cash From Investing Activities -14.97M -10.38M
Cash From Financing Activities 19.58M 8.709M
Net Change In Cash 208.3M 52.59M
YoY Change -820.66% -40.47%
FREE CASH FLOW
Cash From Operating Activities $203.7M $54.26M
Capital Expenditures $41.95M $27.80M
Free Cash Flow $161.7M $26.46M
YoY Change 457.59% 54.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Entity Central Index Key
EntityCentralIndexKey
0001237831
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35621
dei Entity Registrant Name
EntityRegistrantName
GLOBUS MEDICAL, INC.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3744954
dei Entity Address Address Line1
EntityAddressAddressLine1
2560 General Armistead Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Audubon
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19403-5214
dei City Area Code
CityAreaCode
610
dei Local Phone Number
LocalPhoneNumber
930-1800
dei Security12b Title
Security12bTitle
Class A Common Stock, par value $.001 per share
dei Trading Symbol
TradingSymbol
GMED
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
135407017
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
410424000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
467292000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
82509000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
50497000
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
19256000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
8934000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
611784000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
503235000
CY2024Q2 us-gaap Inventory Net
InventoryNet
770463000
CY2023Q4 us-gaap Inventory Net
InventoryNet
848135000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
46213000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
44580000
CY2024Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2498000
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
1635000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
1923891000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1915374000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
480290000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
425695000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
571776000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
586932000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
53881000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
59931000
CY2024Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
27795000
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
75428000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
866565000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
924603000
CY2024Q2 us-gaap Goodwill
Goodwill
1454117000
CY2023Q4 us-gaap Goodwill
Goodwill
1434540000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
77569000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
78590000
CY2024Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
18199000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
10685000
CY2024Q2 us-gaap Assets
Assets
4993793000
CY2023Q4 us-gaap Assets
Assets
5086083000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
67163000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
56671000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
215885000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
240460000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11118000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11967000
CY2024Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
11429000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
3845000
CY2024Q2 us-gaap Senior Notes Current
SeniorNotesCurrent
430485000
CY2024Q2 gmed Business Acquisition Liabilities Current
BusinessAcquisitionLiabilitiesCurrent
38221000
CY2023Q4 gmed Business Acquisition Liabilities Current
BusinessAcquisitionLiabilitiesCurrent
61035000
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19845000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
18369000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
794146000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
392347000
CY2024Q2 gmed Business Acquisition Liabilities Noncurrent
BusinessAcquisitionLiabilitiesNoncurrent
83111000
CY2023Q4 gmed Business Acquisition Liabilities Noncurrent
BusinessAcquisitionLiabilitiesNoncurrent
78323000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
87702000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
91037000
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
417400000
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
27264000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
84421000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
25205000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
24596000
CY2024Q2 us-gaap Liabilities
Liabilities
1017428000
CY2023Q4 us-gaap Liabilities
Liabilities
1088124000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2913609000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2870749000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11851000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10192000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1074472000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1137266000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3976365000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3997959000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4993793000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5086083000
CY2024Q2 us-gaap Revenues
Revenues
629691000
CY2023Q2 us-gaap Revenues
Revenues
291615000
us-gaap Revenues
Revenues
1236357000
us-gaap Revenues
Revenues
568303000
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
260040000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
76473000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
501527000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
147298000
CY2024Q2 us-gaap Gross Profit
GrossProfit
369651000
CY2023Q2 us-gaap Gross Profit
GrossProfit
215142000
us-gaap Gross Profit
GrossProfit
734830000
us-gaap Gross Profit
GrossProfit
421005000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37698000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21347000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
94966000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42429000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
238119000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
120069000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
486829000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
242485000
CY2024Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
1335000
CY2023Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
-2740000
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
1304000
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
-2740000
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
29709000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4547000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
59385000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9148000
CY2024Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
13734000
CY2023Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
5707000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
16152000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
7068000
CY2024Q2 us-gaap Restructuring Costs
RestructuringCosts
-566000
us-gaap Restructuring Costs
RestructuringCosts
18575000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
320029000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
148930000
us-gaap Operating Expenses
OperatingExpenses
677211000
us-gaap Operating Expenses
OperatingExpenses
298390000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
49622000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
66212000
us-gaap Operating Income Loss
OperatingIncomeLoss
57619000
us-gaap Operating Income Loss
OperatingIncomeLoss
122615000
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2335000
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
8294000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-4229000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
14791000
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-703000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-548000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-16074000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-336000
CY2024Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
997000
CY2023Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
716000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1707000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
793000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2041000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8462000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18596000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15248000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
47581000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
74674000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
39023000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
137863000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15821000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16962000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14380000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31022000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
31760000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
57712000
us-gaap Net Income Loss
NetIncomeLoss
24643000
us-gaap Net Income Loss
NetIncomeLoss
106841000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
492000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
40000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
871000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4338000
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1298000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
315000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2530000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1225000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-806000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
355000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1659000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5563000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
30954000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
58067000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
22984000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
112404000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.06
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.05
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135195000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100373000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135276000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100326000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
136979000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101782000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
136836000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101989000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3997959000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17281000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
336000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3413000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5343000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7970000
CY2024Q1 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
83315000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3922361000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12844000
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
181000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14239000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
91000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
30954000
CY2024Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
4123000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3976365000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1846373000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9032000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
219000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4859000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
54337000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1914820000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8639000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
340000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3199000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
58067000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1985065000
us-gaap Net Income Loss
NetIncomeLoss
24643000
us-gaap Net Income Loss
NetIncomeLoss
106841000
gmed Acquired Research And Development In Process
AcquiredResearchAndDevelopmentInProcess
12613000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
118849000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
36183000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
14000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-786000
us-gaap Inventory Write Down
InventoryWriteDown
10498000
us-gaap Inventory Write Down
InventoryWriteDown
3972000
gmed Amortization Of Inventory Fair Value Step Up
AmortizationOfInventoryFairValueStepUp
107341000
gmed Amortization Of Note Fair Value Step Up
AmortizationOfNoteFairValueStepUp
13315000
us-gaap Share Based Compensation
ShareBasedCompensation
30073000
us-gaap Share Based Compensation
ShareBasedCompensation
17542000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
11481000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1863000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
12739000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3280000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-65275000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-11160000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-464000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-129000
us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
16965000
us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
1490000
us-gaap Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax
-6558000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
124206000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
28237000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
22855000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
38658000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2001000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2100000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
11561000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2769000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-28951000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-888000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
6777000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
3047000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
106645000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
88341000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
12174000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
81381000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
21709000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
159328000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
7404000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
21788000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
56366000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33859000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
17535000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
2662000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-56962000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
63214000
gmed Payment Of Business Acquisition Liabilities
PaymentOfBusinessAcquisitionLiabilities
33921000
gmed Payment Of Business Acquisition Liabilities
PaymentOfBusinessAcquisitionLiabilities
4034000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17651000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8058000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
5955000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
84787000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-107012000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4024000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
461000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
407000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-56868000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
155986000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
467292000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
150466000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
410424000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
306452000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
71586000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
38979000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
9508000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5366000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Prior Period Reclassifications</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Certain prior period amounts have been reclassified to conform to the current period presentation. “Operating lease right of use assets” was reclassified out of “Other assets”, and “Operating lease liabilities” were reclassified out of “Accrued expenses” and “Other liabilities”, respectively, depending on the short-term and long-term nature, on our consolidated balance sheets.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are determined to be necessary. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Significant areas that require estimates include revenue recognition, intangible assets, business acquisition liabilities, allowance for doubtful accounts, stock-based compensation, reserves for excess and obsolete inventory, fair value measurements, useful lives of assets, the outcome of litigation, recoverability of intangible assets and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.</span></p>
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
27749000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-13548000
us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
15660000
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
29861000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2024Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2024Q2 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2024Q2 us-gaap Revenues
Revenues
629691000
CY2023Q2 us-gaap Revenues
Revenues
291615000
us-gaap Revenues
Revenues
1236357000
us-gaap Revenues
Revenues
568303000
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
83413000
CY2024Q2 gmed Available For Sale Debt Securities Current Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2024Q2 gmed Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax
906000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
82509000
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
28212000
CY2024Q2 gmed Available For Sale Debt Securities Noncurrent Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax
417000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
27795000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
51630000
CY2023Q4 gmed Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax
1133000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
50497000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
76749000
CY2023Q4 gmed Available For Sale Debt Securities Noncurrent Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax
1321000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
75428000
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
243685000
CY2024Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
432159000
CY2024Q2 gmed Bifurcated Convertible Option On Convertible Debt
BifurcatedConvertibleOptionOnConvertibleDebt
471000
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
121332000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
203689000
CY2023Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
417363000
CY2023Q4 gmed Bifurcated Convertible Option On Convertible Debt
BifurcatedConvertibleOptionOnConvertibleDebt
687000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
139358000
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
120846000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
103349000
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
35743000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
37321000
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
613874000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
707465000
CY2024Q2 us-gaap Inventory Net
InventoryNet
770463000
CY2023Q4 us-gaap Inventory Net
InventoryNet
848135000
CY2024Q2 gmed Net Adjustment To Cost Of Sales Related To Excess And Obsolete Inventory
NetAdjustmentToCostOfSalesRelatedToExcessAndObsoleteInventory
6600000
CY2023Q2 gmed Net Adjustment To Cost Of Sales Related To Excess And Obsolete Inventory
NetAdjustmentToCostOfSalesRelatedToExcessAndObsoleteInventory
1900000
CY2024Q2 gmed Excess And Obsolete Related Provisions
ExcessAndObsoleteRelatedProvisions
8600000
CY2023Q2 gmed Excess And Obsolete Related Provisions
ExcessAndObsoleteRelatedProvisions
3400000
CY2024Q2 gmed Inventory Sales And Disposals Related Provisions
InventorySalesAndDisposalsRelatedProvisions
2000000.0
CY2023Q2 gmed Inventory Sales And Disposals Related Provisions
InventorySalesAndDisposalsRelatedProvisions
1500000
gmed Net Adjustment To Cost Of Sales Related To Excess And Obsolete Inventory
NetAdjustmentToCostOfSalesRelatedToExcessAndObsoleteInventory
10500000
gmed Net Adjustment To Cost Of Sales Related To Excess And Obsolete Inventory
NetAdjustmentToCostOfSalesRelatedToExcessAndObsoleteInventory
4000000.0
gmed Excess And Obsolete Related Provisions
ExcessAndObsoleteRelatedProvisions
13800000
gmed Excess And Obsolete Related Provisions
ExcessAndObsoleteRelatedProvisions
6900000
gmed Inventory Sales And Disposals Related Provisions
InventorySalesAndDisposalsRelatedProvisions
3300000
gmed Inventory Sales And Disposals Related Provisions
InventorySalesAndDisposalsRelatedProvisions
2900000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1052066000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1012627000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
480290000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
425695000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
571776000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
586932000
CY2024Q2 us-gaap Depreciation
Depreciation
33880000
CY2023Q2 us-gaap Depreciation
Depreciation
13528000
us-gaap Depreciation
Depreciation
59464000
us-gaap Depreciation
Depreciation
27035000
CY2022Q4 us-gaap Goodwill
Goodwill
197471000
CY2023 us-gaap Goodwill Other Increase Decrease
GoodwillOtherIncreaseDecrease
1235890000
CY2023 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
1179000
CY2023Q4 us-gaap Goodwill
Goodwill
1434540000
us-gaap Goodwill Other Increase Decrease
GoodwillOtherIncreaseDecrease
20953000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-1376000
CY2024Q2 us-gaap Goodwill
Goodwill
1454117000
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1060078000
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
193513000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
866565000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1062341000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
137738000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
924603000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
59912000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
113882000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
110202000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
109219000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
105764000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
367586000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
866565000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
114558000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
140817000
CY2024Q2 gmed Accrued Liabilities Legal And Other Settlements And Expenses
AccruedLiabilitiesLegalAndOtherSettlementsAndExpenses
4342000
CY2023Q4 gmed Accrued Liabilities Legal And Other Settlements And Expenses
AccruedLiabilitiesLegalAndOtherSettlementsAndExpenses
9335000
CY2024Q2 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
27449000
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
23726000
CY2024Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
10271000
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
10130000
CY2024Q2 us-gaap Accrued Exchange Fee Rebate Current
AccruedExchangeFeeRebateCurrent
32723000
CY2023Q4 us-gaap Accrued Exchange Fee Rebate Current
AccruedExchangeFeeRebateCurrent
27605000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
26542000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
28847000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
215885000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
240460000
CY2024Q2 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
29600000
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
1600000
CY2024Q2 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
49.67
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
52.14
CY2024Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1500000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
84800000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
775000000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
31760000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
57712000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
24643000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
106841000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
31760000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
57712000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
24643000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
106841000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135195000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100373000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135276000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100326000
CY2024Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1784000
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1409000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1559000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1663000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
136979000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101782000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
136836000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101989000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.06
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.05
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15045000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5768000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22107000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5576000
CY2024Q2 gmed Share Based Compensation Number Of Stock Plans
ShareBasedCompensationNumberOfStockPlans
4
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11401000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
53.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2331000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
53.20
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
441000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
39.69
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
279000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
58.55
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13012000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
53.41
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
203489000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7533000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
51.29
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M18D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
133357000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5478000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
56.34
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
70132000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7100000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2800000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
9900000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
8100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0402
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0474
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0345
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0410
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.370
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.389
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.350
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.380
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12813000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8589000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30073000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17542000
CY2024Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
31000
CY2023Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
50000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
53000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
128000
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
12844000
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
8639000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
30126000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
17670000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
109500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M28D
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.332
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.227
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.369
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.225
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
-488000
us-gaap Restructuring Charges
RestructuringCharges
23474000
CY2024Q1 us-gaap Restructuring Reserve
RestructuringReserve
10638000
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
-488000
us-gaap Restructuring Charges
RestructuringCharges
23474000
CY2024Q2 us-gaap Payments For Restructuring
PaymentsForRestructuring
1142000
us-gaap Payments For Restructuring
PaymentsForRestructuring
9645000
CY2024Q2 us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
78000
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
4899000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
8930000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
8930000
gmed Lease Term That Are Not Recognized As Right Of Use Assets Or Lease Liabilities
LeaseTermThatAreNotRecognizedAsRightOfUseAssetsOrLeaseLiabilities
P12M
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
53881000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
59931000
CY2024Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1660000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
797000
CY2024Q2 gmed Total Leased Assets
TotalLeasedAssets
55542000
CY2023Q4 gmed Total Leased Assets
TotalLeasedAssets
60728000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11118000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11967000
CY2024Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1038000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
475000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
87702000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
91037000
CY2024Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
684000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
337000
CY2024Q2 gmed Total Lease Liability
TotalLeaseLiability
100542000
CY2023Q4 gmed Total Lease Liability
TotalLeaseLiability
103816000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
6593000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
982000
us-gaap Operating Lease Cost
OperatingLeaseCost
12200000
us-gaap Operating Lease Cost
OperatingLeaseCost
1930000
CY2024Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
165000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
348000
CY2024Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
27000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
56000
CY2024Q2 us-gaap Lease Cost
LeaseCost
6785000
CY2023Q2 us-gaap Lease Cost
LeaseCost
982000
us-gaap Lease Cost
LeaseCost
12604000
us-gaap Lease Cost
LeaseCost
1930000
CY2024Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
632000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
8916000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
849000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
15505000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
314000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
14128000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
18000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
12942000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
4000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
11820000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
74150000
CY2024Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1818000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
137461000
CY2024Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
97000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
38641000
CY2024Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
1722000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
98820000
CY2024Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1038000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11118000
CY2024Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
684000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
87702000
us-gaap Operating Lease Payments
OperatingLeasePayments
9785000
us-gaap Operating Lease Payments
OperatingLeasePayments
1248000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
668000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
611000
gmed Total Cash Paid For Amounts Included In Measurement Of Lease Liabilities
TotalCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
11064000
gmed Total Cash Paid For Amounts Included In Measurement Of Lease Liabilities
TotalCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
1248000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1507000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2527000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y1M6D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M18D
CY2024Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.053
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.036
CY2024Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.050
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024Q2 us-gaap Revenues
Revenues
629691000
CY2023Q2 us-gaap Revenues
Revenues
291615000
us-gaap Revenues
Revenues
1236357000
us-gaap Revenues
Revenues
568303000
CY2024Q2 us-gaap Noncurrent Assets
NoncurrentAssets
571776000
CY2023Q4 us-gaap Noncurrent Assets
NoncurrentAssets
586932000

Files In Submission

Name View Source Status
0001562762-24-000199-index-headers.html Edgar Link pending
0001562762-24-000199-index.html Edgar Link pending
0001562762-24-000199.txt Edgar Link pending
0001562762-24-000199-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gmed-20240630.xsd Edgar Link pending
gmed-20240630x10q.htm Edgar Link pending
gmed-20240630xex31_1.htm Edgar Link pending
gmed-20240630xex31_2.htm Edgar Link pending
gmed-20240630xex32.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
gmed-20240630_cal.xml Edgar Link unprocessable
gmed-20240630_def.xml Edgar Link unprocessable
gmed-20240630x10q_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
gmed-20240630_lab.xml Edgar Link unprocessable
gmed-20240630_pre.xml Edgar Link unprocessable